1-(3-Methyl-furo[2,3-c]pyridin-5-yl)-ethanol | 185220-90-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃吡啶类
• 英文名称: 1-(3-Methyl-furo[2,3-c]pyridin-5-yl)-ethanol
• 英文别名: 1-(3-Methylfuro[2,3-c]pyridin-5-yl)ethanol
• CAS: 185220-90-0
• 化学式: C₁₀H₁₁NO₂
• 分子量: 177.203
• InChiKey: QKPRMHFCRFIAPV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(3-Methyl-furo[2,3-c]pyridin-5-yl)-ethanol 在 sodium hydroxide 、 Porcine pancreatic lipase type II 作用下， 以 甲醇 、 乙醚 为溶剂， 反应 169.0h， 生成 (R)-1-(3-Methyl-furo[2,3-c]pyridin-5-yl)-ethanol
  参考文献：
  名称：

  Stereoselective Synthesis of Furo[2,3-c]pyridine Pyrimidine Thioethers, A New Class of Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors

  摘要：

  An efficient stereoselective total synthesis of the furo[2,3-c]pyridine thiopyrimidine HIV-1 reverse transcriptase inhibitors, PNU-142721 and PNU-109886, has been developed. A convergent approach was utilized, providing direct access to the desired (S)-configuration of the molecule by making use of the alkylation of 4-amino-6-chloro-2-thiopyrimidine with the appropriate (R)-1-chloroethyl furo[2,3-c]pyridine intermediates. The successful preparation makes use of an efficient enzymatic kinetic resolution of the key 1-hydroxyethyl furo[2,3-c]pyridine intermediates to establish stereochemical control of the respective stereogenic centers. In addition, a workable asymmetric reduction strategy was developed for the synthesis of PNU-109886. Prudent reagent selection for the chlorination required for the final coupling reactions allowed for maintenance of the stereochemical integrity of the target compounds. Structural assignment of the absolute configuration of PNU-142721 and PNU-109886 as the (S)-enantiomer was confirmed by X-ray crystallographic analysis.

  DOI：

  10.1021/jo9810359
• 作为产物：
  描述：

  2-chloro-3-hydroxy-6-(1-hydroxyethyl)-pyridine 在 palladium hydroxide - carbon 吡啶 、 sodium hydroxide 、 偶氮二异丁腈 、 氢气 、 碘 、 三正丁基氢锡 、 四氯苯醌 、 sodium hydride 、 potassium carbonate 作用下， 以 乙醇 、 水 、 苯 为溶剂， 25.0 ℃ 、151.68 kPa 条件下， 反应 55.0h， 生成 1-(3-Methyl-furo[2,3-c]pyridin-5-yl)-ethanol
  参考文献：
  名称：

  Stereoselective Synthesis of Furo[2,3-c]pyridine Pyrimidine Thioethers, A New Class of Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors

  摘要：

  An efficient stereoselective total synthesis of the furo[2,3-c]pyridine thiopyrimidine HIV-1 reverse transcriptase inhibitors, PNU-142721 and PNU-109886, has been developed. A convergent approach was utilized, providing direct access to the desired (S)-configuration of the molecule by making use of the alkylation of 4-amino-6-chloro-2-thiopyrimidine with the appropriate (R)-1-chloroethyl furo[2,3-c]pyridine intermediates. The successful preparation makes use of an efficient enzymatic kinetic resolution of the key 1-hydroxyethyl furo[2,3-c]pyridine intermediates to establish stereochemical control of the respective stereogenic centers. In addition, a workable asymmetric reduction strategy was developed for the synthesis of PNU-109886. Prudent reagent selection for the chlorination required for the final coupling reactions allowed for maintenance of the stereochemical integrity of the target compounds. Structural assignment of the absolute configuration of PNU-142721 and PNU-109886 as the (S)-enantiomer was confirmed by X-ray crystallographic analysis.

  DOI：

  10.1021/jo9810359

文献信息

• [EN] ALPHA-SUBSTITUTED PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS AS INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE<br/>[FR] UTILISATION DE COMPOSES A BASE DE PYRIMIDINE-THIOALKYLE A SUBSTITUTION alpha ET D'ALKYLETHER EN TANT QU'INHIBITEURS DE LA TRANSCRIPTASE INVERSE VIRALE
  申请人：PHARMACIA & UPJOHN COMPANY

  公开号：WO1996035678A1

  公开（公告）日：1996-11-14

  (EN) The subject invention relates to pyrimidine-thioalkyl and alkylether compounds of Formula (I) and pyrimidine-thioalkyl and alkylethers of Formula (IA), namely the compounds of Formula (I) where R4 is selected from the group consisitng of -H or-NR15R16 where R15 is -H and R16 is -H, C1-C6 alkyl, NH2 or R15 and R16 taken together with the -N form 1-pyrrolidino, 1-morpholino or 1-piperidino; and R6 is selected from the group consisting of -H, or halo (preferably -Cl); with the overall proviso that R4 and R6 are not both -H. The compounds of Formula (IA) are useful in the treatment of individuals who are HIV positive being inhibitors of viral reverse transcriptase.(FR) L'invention concerne des composés à base de pyrimidine-thioalkyle et d'alkyléther de formule (I) ainsi qu'à base de pyrimidine-thioalkyle et d'alkyléther de formule (IA), c'est-à-dire les composés de la formule (I) où R4 est choisi dans le groupe consistant en -H ou NR15R16, où R15 représente -H et R16 H, un alkyle en C1-C6, -NH2 ou bien R15 et R16, pris conjointement avec le -N, forment 1-pyrrolidino, 1-morpholino ou 1-piperidino et où R6 est choisi dans le groupe consistant en -H ou halo (de préférence -CI), à la condition générale que R4 et R6 ne représentent pas tous les deux -H. Les composés de la formule IA, étant des inhibiteurs de la transcriptase inverse virale, s'avèrent efficaces dans le traitement de personnes séropositives au VIH.

  本发明涉及式（I）的嘧啶硫代烷基和烷基醚化合物以及式（IA）的嘧啶硫代烷基和烷基醚化合物，即式（I）的化合物，其中R4选择自-H或-NR15R16的群组，其中R15为-H，R16为-H，C1-C6烷基，NH2或R15和R16共同与-N形成1-吡咯啉基，1-吗啉基或1-哌啶基；而R6选择自-H或卤（优选为-Cl）的群组，总的条件是R4和R6不同时为-H。式（IA）的化合物在治疗HIV阳性个体中是病毒反转录酶抑制剂。
• Process for producing optically active pyridineethanol derivatives
  申请人：Kaneka Corporation

  公开号：US20040043460A1

  公开（公告）日：2004-03-04

  The present invention relates to a method of producing an optically active pyridineethanol derivative. More particularly, it relates to a method of producing an optically active polycyclic pyridineethanol derivative by causing an enzyme or enzyme source to act on polycyclic acetylpyridine derivatives. The present invention also relates to a novel enzyme which can be used in the production method mentioned above, a DNA coding for said enzyme, a recombinant vector having said DNA, and a transformant having said recombinant vector. The invention further relates to a method of producing an optically active polycyclic pyridineethanol derivative by causing the above novel enzyme or the above transformant to act on optically inactive polycyclic pyridineethanol derivatives.

  本发明涉及一种制备光学活性吡啶乙醇衍生物的方法。更具体地说，它涉及通过使酶或酶源作用于多环乙酰吡啶衍生物来制备光学活性多环吡啶乙醇衍生物的方法。本发明还涉及一种新的酶，可用于上述制备方法，以及编码该酶的DNA，具有该DNA的重组载体和具有该重组载体的转化体。本发明还涉及一种通过使上述新酶或上述转化体作用于光学不活性多环吡啶乙醇衍生物来制备光学活性多环吡啶乙醇衍生物的方法。
• PROCESS FOR PRODUCING OPTICALLY ACTIVE PYRIDINEETHANOL DERIVATIVES
  申请人：KANEKA CORPORATION

  公开号：EP1116795A1

  公开（公告）日：2001-07-18

  The present invention relates to a method of producing an optically active pyridineethanol derivative. More particularly, it relates to a method of producing an optically active polycyclic pyridineethanol derivative by causing an enzyme or enzyme source to act on polycyclic acetylpyridine derivatives. The present invention also relates to a novel enzyme which can be used in the production method mentioned above, a DNA coding for said enzyme, a recombinant vector having said DNA, and a transformant having said recombinant vector. The invention further relates to a method of producing an optically active polycyclic pyridineethanol derivative by causing the above novel enzyme or the above transformant to act on optically inactive polycyclic pyridineethanol derivatives.

  本发明涉及一种生产光学活性吡啶乙醇衍生物的方法。更具体地说，它涉及一种通过使酶或酶源作用于多环乙酰基吡啶衍生物来生产光学活性多环吡啶乙醇衍生物的方法。 本发明还涉及一种可用于上述生产方法的新型酶、编码所述酶的 DNA、具有所述 DNA 的重组载体以及具有所述重组载体的转化体。 本发明还涉及一种生产光学活性多环吡啶乙醇衍生物的方法，其方法是使上述新型酶或上述转化体作用于光学无活性的多环吡啶乙醇衍生物。
• Alpha-substituted pyrimidine-thioalkyl and alkylether compounds
  申请人：PHARMACIA & UPJOHN COMPANY

  公开号：EP1449835A2

  公开（公告）日：2004-08-25

  The subject invention relates to pyrimidine-thioalkyl and alkylether compounds of Formula I and pyrimidine-thioalkyl and alkylethers of Formula IA, namely the compounds of Formula I where R4 is selected from the group consisting of -H or -NR15R16 where R15 is -H and R16 is -H, C1-C6 alkyl, -NH2 or R15 and R16 taken together with the -N form 1-pyrrolidino, 1-morpholino or 1-piperidino; and R6 is selected from the group consisting of -H, or halo (preferably -CI); with the overall provisio that R4 and R6 are not both -H; The compounds of Formula IA are useful in the treatment of individuals who are HIV positive being inhibitors of viral reverse transcriptase.

  本发明涉及式 I 的嘧啶硫烷基和烷基醚化合物 和式 IA 的嘧啶硫代烷基和烷基醚，即式 I 的化合物，其中 R4 选自由-H 或-NR15R16 组成的组，其中 R15 为-H，R16 为-H、C1-C6 烷基、-NH2 或 R15 和 R16 与-N 共同形成 1-吡咯烷基、1-吗啉基或 1-哌啶基；以及 R6 选自-H 或卤代物（最好是-CI）组成的组；但 R4 和 R6 不能都是-H； 式 IA 的化合物作为病毒逆转录酶的抑制剂，可用于治疗 HIV 阳性患者。
• ALPHA-SUBSTITUTED PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS AS INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE
  申请人：PHARMACIA & UPJOHN COMPANY

  公开号：EP0824524A1

  公开（公告）日：1998-02-25